🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Eisai clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA, UK, China and Ireland registers with Eisai as lead sponsor. Synced 26 Sep 2026
18Current trials
4Recruiting now
13Drugs in these trials
4Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Eisai is the lead sponsor of 18 current clinical trials in our USA, UK, China and Ireland registers. 4 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Lecanemab, Lenvatinib and E2086. The most-studied condition is Alzheimer's Disease.

ClinicalTrials.gov trials by status

  • Recruiting422%
  • Not yet open211%
  • Active, closed1267%

Trials by phase

  • Observational528%
  • Phase 1422%
  • Phase 2422%
  • Phase 3317%
  • Phase 1/2211%
01

Clinical trials sponsored by Eisai

18 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT04300556 · ClinicalTrials.gov ↗ · Solid Tumor
Phase 1/2 Recruiting 2020-08 UK, USA
A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
NCT07493265 · ClinicalTrials.gov ↗ · Narcolepsy
Drug: E2086
Phase 2 Recruiting 2026-03 USA, China
A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's Disease
NCT07821658 · ClinicalTrials.gov ↗ · Alzheimer's Disease
Observational Recruiting 2025-05 USA
A Study of E6742 in Participants With Systemic Lupus Erythematosus
NCT07515014 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus
Phase 2 Recruiting 2026-03 China
A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants
NCT07766369 · Healthy Volunteers
Drug: E2086
Phase 1 Not yet open 2026-08 USA
A Postmarketing Study of LEQEMBI in United Kingdom (UK) Participants With Alzheimer's Disease (AD)
NCT07781345 · ClinicalTrials.gov ↗ · Alzheimers Disease
Observational Not yet open 2026-08 UK
Study of E7386 in Participants With Selected Advanced Neoplasms
NCT03264664 · Advanced Neoplasms
Drug: E7386
Phase 1 Active, closed 2017-07 UK, USA
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
NCT03887455 · Early Alzheimer's Disease
Drug: Lecanemab
Phase 3 Active, closed 2019-03 UK, USA, China
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
NCT02811861 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma
Phase 3 Active, closed 2016-10 Ireland, UK, USA
A Study of Oral E1018 in Healthy Adult Participants
NCT06854042 · Malaria, Healthy Participants
Phase 1 Active, closed 2025-02 USA
A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control Population
NCT06744673 · Sleep Initiation and Maintenance Disorders, Pregnancy
Observational Active, closed 2025-01 USA
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
NCT04288089 · ClinicalTrials.gov ↗ · Receptors, Estrogen, Genes, Erbb-2, Breast Neoplasms
Phase 1 Active, closed 2020-04 UK, USA
A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
NCT06043700 · Alzheimer's Disease
Observational Active, closed 2023-09 USA
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
NCT04468659 · ClinicalTrials.gov ↗ · Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
Drug: Lecanemab
Phase 3 Active, closed 2020-07 UK, USA
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797 · ClinicalTrials.gov ↗ · Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular
Phase 1/2 Active, closed 2019-07 USA, China
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
NCT06602258 · ClinicalTrials.gov ↗ · Alzheimer's Disease
Phase 2 Active, closed 2024-09 USA
A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy
NCT04015141 · ClinicalTrials.gov ↗ · Pediatric Epileptic Syndrome, Partial-onset Seizures
Phase 2 Active, closed 2019-05 USA
A Retrospective Database Study for the Development and Validation of Algorithms for Intracerebral Hemorrhage and Seizures in Alzheimer's Disease
NCT07723950 · ClinicalTrials.gov ↗ · Alzheimer's Disease
Observational Active, closed 2026-05 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Eisai trials

13 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Eisai trials

24 conditions
Alzheimer's Disease4Renal Cell Carcinoma1Advanced Neoplasms1Early Alzheimer's Disease1Receptors, Estrogen1Genes, Erbb-21Breast Neoplasms1Solid Tumor1Preclinical Alzheimer's Disease1Early Preclinical Alzheimer's Disease1Alzheimers Disease1Healthy Volunteers1Malaria1Healthy Participants1Sleep Initiation and Maintenance Disorders1Pregnancy1Narcolepsy1Endometrial Neoplasms1Neoplasms1Carcinoma, Hepatocellular1Liver Neoplasms1Pediatric Epileptic Syndrome1Partial-onset Seizures1Systemic Lupus Erythematosus1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA163
Clinical trials in UK71
Clinical trials in China42
Clinical trials in Ireland10

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Alzheimer's Disease

SponsorTrials
Sichuan Provincial People's Hospital2
Denali Therapeutics1
Green Valley (Shanghai) Pharmaceuticals1

Sponsors with the most current trials registered for this condition.

06

Questions about Eisai trials

How many clinical trials does Eisai sponsor?

Eisai is the lead sponsor of 18 current trials on ClinicalTrials.gov in our USA, UK, China and Ireland registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Eisai trials recruiting?

Yes. 4 of its 18 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Eisai testing?

Its current trials name 13 drugs and biologicals as interventions. The most frequent are Lecanemab (3), Lenvatinib (3), E2086 (2), E7386 (2) and Dexamethasone (1). The number in brackets is how many of its trials name each drug.

Does Eisai have clinical trials in Ireland?

Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.